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http://dx.doi.org/10.1016/j.stemcr.2017.04.018SUMMARYRecent studies using defined transcription factors to convert skin fibroblasts into chondrocytes have raised the question ofwhether osteo-
chondroprogenitors expressing SOX9 and RUNX2 could also be generated during the course of the reprogramming process. Here, we
demonstrated that doxycycline-inducible expression of reprogramming factors (KLF4 [K] and c-MYC [M]) for 6 days were sufficient to
convert murine fibroblasts into SOX9+/RUNX2+ cellular aggregates and together with SOX9 (S) promoted the conversion efficiency
when cultured in a defined stem cell medium, mTeSR. KMS-reprogrammed cells possess gene expression profiles akin to those of native
osteo-chondroprogenitors with elevated osteogenic properties and can differentiate into osteoblasts and chondrocytes in vitro, but form
bone tissue upon transplantation under the skin and in the fracture site of mouse tibia. Altogether, we provide a reprogramming strategy
to enable efficient derivation of osteo-chondrogenic cells that may hold promise for cell replacement therapy not limited to cartilage but
also for bone tissues.INTRODUCTION
The formation of skeletal tissues during embryonic devel-
opment not only serves as a structural framework in our
body to fulfill supportive, mechanical, and protective roles
but also contributes to the homeostatic processes in the
adult. The skeletal tissue is mainly derived frommesoderm
with some elements originating from ectoderm. The for-
mation of this is initiated when mesenchymal skeletal
progenitor cells, also known as osteo-chondroprogenitors,
undergo condensation and give rise to either chondrocytes
to form the cartilage or osteoblasts to form the bone. The
transcription regulators SOX9, a member of the Sox family,
and RUNX2, amember of the Runt family, are co-expressed
in osteo-chondroprogenitors, with the former being essen-
tial for its specification and chondrogenic lineage determi-
nation and the latter required for osteoblast cell-fate deter-
mination and early differentiation (Akiyama et al., 2005; Bi
et al., 1999; Komori et al., 1997; Otto et al., 1997). In addi-
tion, several signaling molecules, notably transforming
growth factor b1 (TGF-b1), bone morphogenetic proteins,
fibroblast growth factors (FGFs), and WNTs are also crucial
for establishing and directing differentiation of skeletal
progenitor cells (Liu et al., 2008; Qi et al., 2014; Song
et al., 2009). The ability to translate findings from these
developmental studies to in vitro differentiation into chon-
drogenic and osteogenic lineages from pluripotent or mul-
tipotent embryonic stem cells (ESCs) has opened the doorStem Cell R
This is an open access article under the Cfor the development of cell-based therapies for the treat-
ment of a broad range of skeletal diseases (Hwang et al.,
2008; Pelttari et al., 2008; Wu et al., 2013).
Pluripotent ESCs and induced pluripotent stem cells
(iPSCs) represent a potentially unlimited source of skel-
etal cells for therapeutic applications. Several studies
have established defined culture conditions to direct dif-
ferentiation of mouse/human ESCs and human iPSCs
into chondrogenic lineage (Craft et al., 2013; Umeda
et al., 2015; Yamashita et al., 2015). In addition, the
iPSC reprogramming approach has also been adopted in
generating chondrocyte without passing through a stem
cell state by ectopic expression of defined lineage-specific
transcription factors based on their master-regulatory
roles in chondrogenesis. It has been well established
that SOX9, SOX5, and SOX6 (the SOX trio) are master
regulators of chondrogenesis. Previous studies showed
that conditional ablation of Sox9 gene in limb bud os-
teo-chondrogenitors prior to the onset of chondro-
genic mesenchymal condensation resulted in a complete
absence of cartilage and bone formation, whereas abla-
tion of SOX9 function after mesenchymal condensation
led to the impairment of chondrocyte proliferation
and differentiation, which was predominantly mediated
by the absence of Sox5 and Sox6 expression (Akiyama
et al., 2002; Smits et al., 2001). In addition, the SOX
trio regulates genes coding for the extracellular matrix
components by binding to their enhancers (Bell et al.,eports j Vol. 8 j 1587–1599 j June 6, 2017 j ª 2017 The Author(s). 1587
C BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Transient Formation of SOX9-EGFP+/RUNX2+ Nodules during Induction of Chondrogenic Cells from Dermal Fibroblasts by
KLF4, c-MYC, and SOX9
(A) Schematic showing a direct conversion of mouse dermal fibroblasts (MDFs) prepared from newborn Sox9-EGFP knockin (KI) reporter
mice into chondrocytes by retroviral-mediated expression of KLF4, c-MYC, and SOX9 (KMS). Scale bar, 50 mm. Transduced fibroblasts were
cultured in the standard medium (DMEM + 10% FBS) and monitored daily for the formation of SOX9-EGFP+/RUNX2+ cells up to 14 days (d).
MDFs did not express EGFP prior to retroviral transduction.
(legend continued on next page)
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1997; Bridgewater et al., 1998; Han and Lefebvre, 2008;
Lefebvre et al., 1998; Nagy et al., 2011). Consistently,
adenoviral-mediated expression of the SOX trio is suffi-
cient to transform mouse dermal fibroblasts (MDFs)
into chondrogenic cells expressing cartilage marker genes
and secreting extracellular matrix. However, the induced
cells still expressed fibroblast marker gene, type I collagen,
which could impair the integrity of matrix structure and
function, precluding the use of SOX trio-induced cells for
cartilage repair (Ikeda et al., 2004). This issue was resolved
by another study in which MDFs were converted into
chondrocytes without type I collagen gene expression by
retroviral-mediated expression of two iPSC-reprogram-
ming factors (c-MYC and KLF4) and a master regulator
for chondrogenesis, SOX9 (Hiramatsu et al., 2011).
In addition, this chondrogenic induction did not pass
through a pluripotent state throughout the period of
the reprogramming process (Outani et al., 2011). Subse-
quently, the same research group generated induced
chondrogenic (iChon) cells expressing type II but not
type I COLLAGEN from human dermal fibroblasts with
the same factors (Outani et al., 2013). Both mouse and
human iChon cells produced homogeneous cartilage-
like tissues upon grafting in nude mice (Hiramatsu
et al., 2011; Outani et al., 2013). However, it is not clear
from these studies whether bipotential osteo-chondro-
progenitors are generated during the direct conversion
of fibroblasts into chondrocytes. Thus, it is conceivable
that the ability to generate osteo-chondroprogenitors
by a reprogramming approach with defined factors may
hold promise for cell replacement therapy not limited
to cartilage but also for bone tissues.
In the present study, we took advantage of this lineage-re-
programming approach to examine the possibility of osteo-
chondroprogenitor formationusing Sox9-EGFPknockin (KI)
reporter mice. We identified osteo-chondrogenic cells dur-
ing the course of lineage reprogramming from skin fibro-
blasts to chondrocytes with gene expression profiles and
in vitro differentiation potency comparable with native os-
teo-chondroprogenitors in developing mouse limb bud.
Transplantation of reprogrammed osteo-chondrogenic cells
subcutaneously and into bone lesion site of immunodefi-
cient recipients resulted in bone formation. Together, these
findings demonstrate that by using a transcription factor-
driven reprogramming approachwe can efficiently generate
osteo-chondrogenic cells that readily form bone in vivo.(B) Insets show phase images of KMS-transduced MDFs with nodular a
SOX9-EGFP+ nodules with anti-GFP and anti-RUNX2. Induced nodules
(C) Micrographs of MDFs and KMS-transduced cells on d14. Scale bar,
(D) Quantification of KMS-induced nodules formed upon cultured in th
(E) Quantification of KMS-induced GFP+/RUNX2+ nodules formed up
cultures, mean ± SEM. **p < 0.01, ***p<0.001; Student’s t test.RESULTS
Transient Formation of SOX9-EGFP/RUNX2-
ExpressingCells duringChondrogenic Induction from
Skin Fibroblasts by KLF4, c-MYC, and SOX9
To determine whether cells expressing SOX9 and RUNX2
(SOX9+RUNX2+), which marks osteo-chondroprogenitors,
could be formed during the course of chondrogenic induc-
tion by KLF4, c-MYC, and SOX9 (hereafter abbreviated
as KMS), we performed retroviral-mediated expression of
these factors in 2 3 104 MDFs prepared from new born
Sox9-EGFP knockin (KI) mice, which enabled us tomonitor
daily the expression of EGFP driven by cis-acting elements
of Sox9 over 14 days of culture in conventional medium
(DMEM + 10% fetal bovine serum [FBS]), a time when cells
acquire chondrogenic features based on previous studies
(Figure 1A; Hiramatsu et al., 2011). Thus, EGFP expression
in transformed cells is considered to be an indicator of acti-
vation of Sox9 transcription followed by RUNX2 immuno-
fluorescence to determine co-expression of SOX9-EGFP
and RUNX2. We found that transformed fibroblasts began
to form aggregates and express EGFP as early as day 9 (d9)
post transduction. By d10, initiation of RUNX2 expression
was detectable in EGFP+ aggregates with distinct nodular
appearance, became significant ond12 andd13, anddimin-
ishedorwerebarely observedond14,while EGFPwasmain-
tained fromd9 to d14 (Figure 1B). By d14, cells in the aggre-
gates exhibited typical polygonal-like morphology of
chondrocyte with intense Alcian blue staining compared
with MDFs in spindle shape, indicating production of pro-
teoglycan in transformed cells (Figures 1B and 1C). Quanti-
fication analyses showed that the number of nodules
positive for SOX9-EGFP and RUNX2 (GFP+/RUNX2+)
increased from d10 (24.25% ± 0.829%) to d13 (63.03% ±
2.92%) and significantly reduced on d14 (14.15% ±
3.31%). By contrast, the number of GFP+/RUNX2 nodules
formed were reduced from d11 (40.15% ± 0.59%) to
d13 (9.54% ± 0.51%) but markedly increased on d14
(74.88% ± 1.63%). In addition, we also observed nodules
negative for both EGFP and RUNX2 (GFP/RUNX2)
from d9 (51.19% ± 1.12%) to d14 (23.20% ± 1.96%), but
no nodules expressing RUNX2 alone were obtained
throughout the period of analysis (Figure 1D). Taken
together, these results suggest that transient expression of
GFP+/RUNX2+ nodules were formed during KMS-mediated
chondrogenic induction from skin fibroblasts.ppearance from d9 to d14. Immunofluorescence was performed on
were stained with Alcian blue. Scale bar, 50 mm.
200 mm.
e conventional medium. n = 3 independent experiments, mean ± SD.
on culture in conventional and mTeSR media. n = 3 independent
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Figure 2. Generation of SOX9-EGFP+/RUNX2+ Nodules by Dox-Inducible Lentiviral System
(A) Schematic diagram showing MDFs derived from Sox9-EGFP KI reporter mice were transduced with dox-inducible lentiviral KMS or KM
vectors and treated with dox for 2, 4, 5, 6, 8, and 10 days to assess the formation of SOX9-EGFP+/RUNX2+ nodules.
(B) Panels show that no nodules were formed in MDFs transduced with KMS when treated with dox for 5 days, whereas nodules began to
form on day 10 (d10), expressed GFP and RUNX2 from d11 to d13, and were positive for Alcian blue (inset in bottom right corner) on d14
(legend continued on next page)
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Establishment of Culture Conditions to Promote the
Formation of SOX9-EGFP+/RUNX2+ Cells
The inability of all nodules co-expressing SOX9-EGFP and
RUNX2 suggested a lack of essential components in culture
medium to promote SOX9 and RUNX2 expression in trans-
formed cells. To exploit an appropriate culture condition
for the transduced cells, we first plated KMS-transduced
cells onto SNL feeder cells, which are commonly used as
a feeder layer for the propagation of mouse ESCs, and
examined their ability to support the generation of GFP+/
RUNX2+ cells. However, nodules expressing GFP alone
were still observed from d9 to d14, and the number of nod-
ules co-expressing GFP and RUNX2 did not increase
dramatically and even reduced on d13 compared with
the condition without SNL feeder cells (Figures S1A and
1D). In addition, the number of GFP+/RUNX2+ nodules
was also markedly reduced under the hypoxic condition,
which was shown to promote chondrogenesis via activa-
tion of Sox9 transcription (Figure S1B; Amarilio et al.,
2007). These results suggest that SNL feeder or reduced
oxygen content did not promote efficient generation of
KMS-induced GFP+/RUNX2+ cells.
A defined ESCmedium,mTeSR (StemCell Technologies),
whichmainly contains basic FGF (bFGF), TGF-b1, and LiCl,
was previously found to promote the expansion of human
mesenchymal stem cells that enrich for osteo-chondro-
genic precursors expressing Sox9 and Runx2 genes (Hudson
et al., 2011).We therefore tested whethermTeSRmedium is
able to increase the number of transformed GFP+/RUNX2+
nodules. We obtained a significant increase in the number
of KMS-induced GFP+/RUNX2+ nodules by 18.44% ±
1.41% on d11 and 20.3% ± 2.92% on d13 compared with
the conventional medium. In contrast, the number of
GFP+/RUNX2+ nodules formed was markedly reduced on
d14 (Figure 1E). Importantly, none of the nodules formed
expressed either EGFP or RUNX2 only. These data suggest
that mTeSR medium provided a better culture condition
to promote a transient formation of KMS-induced GFP+/
RUNX2+ cells and was therefore used for subsequent
analyses.upon 6 days of dox treatment. Insets in top right corners show phase
dox treatment, respectively.
(C) Quantification of the number of GFP+/RUNX2+ and GFP/RUNX2 no
6 days of dox treatment in culture.
(D) qPCR analysis of exogenous (ex) Klf4, c-Myc, and Sox9 expression
(E) MDFs transduced with KM were subjected to dox treatment for 5 a
(F) Quantification of the number of GFP+/RUNX2+ and GFP/RUNX2 n
6 days of dox treatment in culture.
(G) Comparison of the number of KMS- and KM-reprogrammed GFP+/
treatment.
Three independent experiments are represented in (C), (D), (F), and (G
0.001. Scale bar in (B) and (E) represents 50 mm.On the other hand, it is also possible that KMS reprog-
rammed a small amount of tissue stem cells present in
the dermal fibroblast culture into GFP+/RUNX2+ nodules
(Sudo et al., 2007). To rule out this possibility, we trans-
duced KMS into ESCs derived from Sox9-EGFP KI mice
and cultured inmTeSR, and found that nodules transiently
expressingGFP fromd14 to d16without RUNX2 co-expres-
sion were observed throughout the period of analysis (Fig-
ure S1C). The lack of sustainedGFP expression could be due
to either early silencing of transgene expression or lack of
essential factors in ESCs to cooperate with the transgene
for the maintenance of SOX9 expression. Nevertheless,
the data suggest that transformed GFP+/RUNX2+ nodules
were unlikely to be derived from resident stem cells in
MDFs.
Generation of SOX9-EGFP+/RUNX2+ Nodules by
Transient Expression of KMS or KM
Since KMS are oncogenes and their continued expression
mediated by retroviral vectors in transformed cells could
lead to tumor formation upon transplantation (Patel and
Yang, 2010), we then examined whether transient expres-
sion of the transgene are sufficient to generate GFP+/
RUNX2+ nodules. To this end, we transduced 2 3 104
MDFs with KMS using doxycycline (dox)-inducible lentivi-
ral vectors and cultured with 1 mg/mL dox in mTeSR me-
dium from d1 to d10 to monitor the formation of GFP+/
RUNX2+ nodules until d14 (Figures 2A and S2A). While
absence of dox treatment did not formGFP+/RUNX2+ nod-
ules at all time points examined, we began to observe KMS-
induced nodules formed on d10, expressing Sox9-EGFP/
RUNX2 from d11 to d14 after withdrawal of dox from d7
onward, and they were intensely stained with Alcian blue
on d14 (Figures 2B and S2A). No nodules expressing either
SOX9-EGFP and/or RUNX2 were formed prior to 6 days of
dox treatment (Figures 2B and S2A). Consistently, exoge-
nous expression of Klf4, c-Myc, and Sox9 were markedly
reduced by d8 following dox withdrawal on d7 (Figure 2D).
Importantly, the number of KMS-reprogrammed GFP+/
RUNX2+ nodules formed between d11 and d14 wereimages of transduced cells and nodules cultured for 5 and 6 days of
dules formed from d9 to d14 in MDFs transduced with KMS following
in transduced cells at d2, d4, d6, and d8.
nd 6 days.
odules formed from d9 to d14 in MDFs transduced with KM following
RUNX2+ nodules formed from d10 to d14 following 6 days of dox
). Data are expressed as means ± SEM. *p < 0.05, **p < 0.01, ***p <
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Figure 3. Expression of Sox9 and Runx2 in KMS-Reprogrammed Nodules
(A) (Top) Isolation of SOX9-EGFP+ cells from E10.5 mouse limb bud (red circle) by fluorescence-activated cell sorting as a positive control
for the real-time qPCR analysis. Wild-type limb bud cells were used as negative control. Scale bar, 500 mm. (Bottom) Immunofluorescence
of sorted GFP+ limb bud cells with antibodies against SOX9 and RUNX2 and cell nuclei were counterstained with DAPI (white arrows). Scale
bar, 5 mm.
(B and C) qPCR analysis of Sox9 (B) and Runx2 (C) transcript levels in sorted GFP+ limb bud cells, MDFs, and KMS-reprogrammed nodules
from day 11 (d11) to d14. Three independent experiments are represented. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01,
***p < 0.001; ns, not significant.similar to those generated by retroviral transduction
(compare Figures 2C and 1E). These results suggest that
transient expression of KMS genes for at least 6 days is
sufficient to generate SOX9-EGFP+/RUNX2+ nodules in ki-
netics and quantities similar to those generated by retro-
viral-mediated expression of the transgene.
We then investigated theminimumnumber of transcrip-
tion factors required for the formation of induced GFP+/
RUNX2+ nodules in mTeSR medium and found that
MDFs transduced with KM genes were also capable of form-
ing GFP+/RUNX2+ from d10 onward after 6 days of dox
treatment, but an approximately 2-fold reduction of their
numbers were obtained compared with KMS between d10
and d14 (Figures 2E and 2G). In contrast, the number of
GFP+/RUNX2+ nodules formed was negligible upon trans-
duction of KS genes (Figure S2B). In addition, fibroblasts
transduced with eitherMS, K, orM genes did not form nod-
ules but remained single cells largely scattered throughout
the medium (Figures S2B and 2C). Some cells were occa-
sionally positive for GFP and RUNX2. We did not observe
fibroblasts expressing GFP and/or RUNX2 upon transduc-
tion of Sox9 gene throughout the period of analysis (Fig-
ure S2B). These results suggest that KLF4 and c-MYC are suf-
ficient to convert fibroblasts into GFP+/RUNX2+ nodules,
albeit at lower efficacy than that of KMS (Figure 2G).1592 Stem Cell Reports j Vol. 8 j 1587–1599 j June 6, 2017Molecular Characterization of Reprogrammed SOX9-
EGFP+/RUNX2+ Nodules
We then examined whether dox-inducible KMS-reprog-
rammed EGFP+/RUNX2+ nodules express genes char-
acteristic of osteo-chondroprogenitors and/or other
mesenchymal lineages by real-time qPCR. We isolated
SOX9-EGFP+ osteo-chondroprogenitors by flow cytometry
from embryonic day 10 (E10) mouse limb bud as a posi-
tive control and MDFs as a negative control. These sorted
cells expressed GFP, SOX9, and RUNX2 in mTeSR me-
dium, confirming their osteo-chondroprogenitor identity
(Figure 3A). We then examined transcript levels of
osteo-chondrogenic and chondrogenic lineage markers
in GFP+/RUNX2+ nodules generated by dox-inducible
KMS or KM between d11 and d14 because none of the
markers examined were detectable prior to d11 (data not
shown). We found that the levels of Sox9, Runx2,
Col2a1, Sox5, and Sox6 transcripts gradually increased
and peaked at d13, similar to their amount detected in
sorted GFP+ limb bud cells (Figures 3B, 3C, and 4A–4C).
By d14, most of the transcripts were maintained in
KMS-reprogrammed nodules (Figures 3B and 4A–4C)
except that Runx2 expression was low (Figure 3C), consis-
tent with its downregulation of protein level (Figure 2B).
In contrast, expression of these genes was relatively low
Figure 4. KMS-Reprogrammed Nodules Express Markers of Osteo-Chondroprogenitor and Chondrogenic Lineages
(A–M) qPCR analysis for the indicated transcript levels in KMS-reprogrammed nodules from day 11 (d11) to d14. Individual mRNA
expression levels were normalized to Gapdh with fold change relative to MDFs. GFP+ limb bud cells, chondrocytes, osteoblasts, and P10
(legend continued on next page)
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in KM-reprogrammed nodules (Figures S3A–S3E). Intrigu-
ingly, the cell-surface marker genes tetraspanin CD9 and
ectonucleotidase CD73, previously shown to enrich os-
teo-chondroprogenitor population with elevated osteo-
genic properties from bone marrow cells, exhibited higher
levels of transcripts in KMS-reprogrammed nodules than
that of sorted GFP+ cells and KM-reprogrammed nodules
(Figures 4D, 4E, S3F, and S3G). In addition, both KMS-
and KM-reprogrammed nodules did not express or ex-
pressed at low levels of markers for hypertrophic chondro-
cyte Col10 and osteoblast lineage, such as osteopontin,
osteocalcin, and osterix, at all time points examined (Fig-
ures 4F–4I and S3H–S3K). In contrast, Col1a1, which is ex-
pressed in MDFs and osteoblasts, was gradually reduced
from d1 to d6 in both KMS- and KM-reprogrammed cells
and remained at low level of expression from d7 to d14,
similar to that of sorted GFP+ cells, indicating that Cola1
expression was silenced in MDFs during the course of re-
programming (Figures 4J and S3L). Since Sox9 and Runx2
genes are also expressed in the prehypertrophic chondro-
cytes, we examined the expression of genes characteristic
of prehypertrophic chondrocytes, Ihh and Ppr. While
growth plate from the tibial epiphyseal cartilage of
neonatal mice expressed high levels of Ihh and Ppr tran-
scripts, neither KMS nor KM activated their levels of
expression, ruling out the possibility that SOX9-EGFP+/
RUNX2+ are prehypertrophic chondrocytes (Figures 4K,
4L, S3M, and S3N). Moreover, we also detected an
elevated level of Gremlin 1 expression, which defines a
distinct population of osteo-chondroreticular stem cells
in the bone marrow (Wang et al., 2015), in KMS-reprog-
rammed nodules at d13 only, whereas its expression was
low in KM nodules (Figures 4M and S3O), suggesting
that GFP+/RUNX2+ nodules may possess skeletal stem
cell features. Consistent with a previous report (Outani
et al., 2013), nodules expressing dox-inducible KMS or
KM were not pluripotent, as indicated by significantly
reduced expression of Oct4 and Sox2 at all times points
examined compared with that of ESCs (Figures S3P and
S3Q). On the other hand, examination of other mesen-
chymal lineage markers showed that KMS- and KM-re-
programmed nodules exhibited a low level of expression
of the adipocyte marker, PPAR-g1 (peroxisome prolifera-
tor-activated receptor g1), which was highly expressed
in adipocytes isolated from epidermal fat pads of adult
mice as a positive control and undetectable in sorted
SOX9-EGFP+ cells (Figure S3R). Lastly, we examined genes
characteristic for mesenchymal stem cells (MSCs) in re-tibial growth plate served as positive controls. Three independent exp
0.05, **p < 0.01, ***p < 0.001; ns, not significant.
(N) Heatmap showing expression levels for the indicated transcripts in
cells.
1594 Stem Cell Reports j Vol. 8 j 1587–1599 j June 6, 2017programmed GFP+/RUNX2+ nodules and detected low
levels of Mmp3 expression and a negligible amount of
Igf2 transcripts in both treatments, compared with a sig-
nificant amount of their transcripts present in mouse
bone marrow-derived MSCs, indicating that reprog-
rammed GFP+/RUNX2+ nodules did not harbor molecular
features of MSCs (Figures S3S and S3T). Altogether, these
results suggest that reprogrammed nodules derived from
dox-inducible KMS exhibited gene expression profiles
closely associated with, if not identical to, native osteo-
chondroprogenitors and may also contain a subpopula-
tion with osteogenic potential (Figure 4N).
Differentiation Potential of Reprogrammed SOX9-
EGFP+/RUNX2+ Nodules
To determine whether KMS- and KM-reprogrammed GFP+/
RUNX2+ nodules are able to differentiate into mesen-
chymal lineages including chondrocytes, osteoblasts,
and adipocytes, we subjected nodules obtained on d13,
when the majority of them are GFP+/RUNX2+, to chondro-
genic, osteogenic, and adipogenic media to interrogate
their differentiation potential. After 14 days of culture,
both KMS- and KM-reprogrammed GFP+/RUNX2+ nodules
were positive for alizarin red S (bone) and Alcian blue (carti-
lage) staining, demonstrating their ability to differentiate
into osteoblasts and chondrocytes, respectively (Figure 5A).
Further molecular characterization revealed that four inde-
pendent reprogrammed cells and sorted GFP+ limb bud
cells after treatment with osteogenic medium exhibited
comparable levels of osteoblast marker expression with
bone marrow-derived osteoblasts as positive control, indi-
cating their osteoblast identity (Figure 5B). However, they
were not able to differentiate into adipocytes as shown by
the absence of oil red O staining (Figure 5A). By contrast,
MDFs did not undergo differentiation into the tri-lineages
whereas the opposite occurred for MSCs, as expected
(Figure 5A). These data suggest that KMS- and KM-reprog-
rammed GFP+/RUNX2+ nodules harbor osteo-chondro-
genic potential in vitro. To further evaluate their differenti-
ation capacity in vivo, we injected 1 3 105 KMS-derived
reprogrammed cells obtained on d13 subcutaneously into
the dorsal flanks of nude mice. After 6 weeks of transplan-
tation, immunofluorescence analysis revealed that donor-
derived GFP+ cells gave rise to tissues expressing RUNX2,
OSTERIX, and TYPE I COLLAGEN (COL1), whereas chon-
drocyte markers, SOX9, and TYPE II COLLAGEN (COL2)
were not detected (Figure 5C). In addition, positive stain-
ing for Von Kossa was observed in the tissue, indicatingeriments are represented. Data are expressed as means ± SEM. *p <
KMS-reprogrammed nodules from d11 to d14 and in GFP+ limb bud
(legend on next page)
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mineralization, and histological analysis further confirmed
their bone identity (n = 8/10, Figure 5C). In contrast, KM-
reprogrammed cells formed neither bone nor cartilage tis-
sues in vivo. These data suggest that KMS-reprogrammed
cells exhibited osteogenic differentiation capacity in vivo.
To further substantiate this observation, we transplanted
1 3 104 KMS-reprogrammed cells obtained on d13 to the
fracture site of adult mouse tibia at the time of injury. After
6 days of transplantation, the grafted GFP+ cells differenti-
ated into tissues expressing RUNX2 and COL1 but not
SOX9within the fracture site (Figure 5D). Histological anal-
ysis revealed that the grafted cells gave rise to tissue with
trabecular bone-like morphologies (n = 9/10; Figure 5D).
Importantly, we did not observe formation of tumor tissues
in both transplantation experiments (Figures 5C and 5D).
Together, these findings further indicate that KMS-re-
programmed GFP+/RUNX2+ nodules, though expressing
markers of osteo-chondroprogenitor and chondrogenic
lineages, possessed elevated osteogenic potency in vivo.DISCUSSION
Direct lineage reprogramming from somatic cells orches-
trated by overexpression of defined transcription factors
has been successfully adopted in generating various
tissue-specific cell types and their stem-like precursors
including neurons, neural stem cells, cardiomyocytes,
chondrocytes, hepatocytes, hepatic stem cells, and blood
progenitor cells (Efe et al., 2011; Hiramatsu et al., 2011;
Huang et al., 2011; Ieda et al., 2010; Outani et al., 2013;
Pang et al., 2011; Qian et al., 2012; Szabo et al., 2010; Thier
et al., 2012; Vierbuchen et al., 2010; Yu et al., 2013).
Whether a similar approach could be used to generate os-
teo-chondroprogenitors expressing SOX9/RUNX2 has not
been shown. Here we closely investigated the course of
lineage reprogramming from dermal fibroblasts to chon-Figure 5. Differentiation Potency of Reprogrammed SOX9-EGFP+/
(A) Alizarin red S, Alcian blue, and oil red O staining were performed o
marrow-derived mesenchymal stem cells (MSCs) served as a positive c
(B) qPCR analysis for the levels of indicated transcripts in four indepen
limb bud cells after treatment with osteogenic differentiation medium
fold change relative to sorted GFP+ limb bud cells. Osteoblasts serve
sented. Data are expressed as means ± SEM. ***p < 0.001.
(C) Immunofluorescence with antibodies against GFP, RUNX2, OSTER
derived from KMS-reprogrammed cells. White dotted lines in the in
staining of sections indicate formation of bone tissue.
(D) Phase-contrast image of transplanted KMS-reprogrammed nodu
Immunofluorescence with antibodies against GFP, RUNX2, COL1, and
reprogrammed cells. White dotted lines indicate tissue boundary. Rep
trabecular bone-like morphologies.
Scale bars, 30 mm (A) and 100 mm (C and D).
1596 Stem Cell Reports j Vol. 8 j 1587–1599 j June 6, 2017drocytes by using Sox9-EGFP reporter mice and immunocy-
tochemistry for RUNX2, revealing that chondrogenic
induction passed through an intermediate state of osteo-
chondroprogenitor-like cells with gene expression profiles
akin to those of native osteo-chondroprogenitors in devel-
oping mouse limb bud and osteogenic potency in vivo.
Our studies also revealed that reduced oxygen content
did not promote the formation of SOX9+/RUNX2+ nod-
ules, in contrast to previous studies showing that hypoxia
controls differentiation of prechondrogeneic cells partly
through regulation of Sox9 gene expression (Amarilio
et al., 2007). The reasons for the discrepancy are not clear.
One possibility could be the lack of hypoxic response in the
transformed cells. By contrast, we found that mTeSR me-
dium provided a better culture condition for enhancement
of the formation of SOX9-EGFP+/RUNX2+ nodules during
chondrogenic reprogramming. A previous study showed
that mTeSR mainly contains bFGF, TGF-b1, and LiCl,
capable of supporting the preferential enrichment ofmulti-
potent human MSCs with osteo-chondrogenic potential
(Hudson et al., 2011). TGF-b1 and FGF2 have been shown
to be the inducers of Sox9 gene expression and thus pro-
mote chondrogenesis in mesenchymal lineages, while
LiCl is an activator of canonical Wnt signaling that was
shown to promote osteogenesis by directly stimulating
Runx2 gene expression via its downstream effector, b-cate-
nin (Gaur et al., 2005; Handorf and Li, 2011; Lorda-Diez
et al., 2009). Altogether, our data suggest that the presence
of these essential components in mTeSR medium could
facilitate the induction of Sox9 and Runx2 gene expression
in reprogrammed nodules.
Our results further revealed that transient expression of
KMS genes for at least 6 days led to the subsequent forma-
tion of SOX9-EGFP+/RUNX2+ nodules between d11 to
d13 in similar kinetics and quantities to those generated
by retroviral-mediated transgene expression, suggesting
that these factors are sufficient to promote and sustainRUNX2+ Nodules
n in vitro differentiated nodules transduced with KMS or KM. Bone
ontrol and MDFs as a negative control.
dent KMS-reprogrammed nodules and osteoblasts derived from GFP+
. Individual mRNA expression levels were normalized to Gapdh with
d as a positive control. Three independent experiments are repre-
IX, COL1, COL2, and SOX9 (inset) on paraffin sections of tissues
set indicate tissue boundary. Representative Von Kossa and H&E
le into the fracture site of mouse tibia (dotted box with arrow).
SOX9 on sections of mouse fracture tibia transplanted with KMS-
resentative H&E staining of serial section shows grafted tissue with
reprogramming events even in the absence of continued
transgene expression. It has been demonstrated that
c-MYC and KLF4 are oncogenic factors, which induce
epigenetic changes in gene expression to trigger transfor-
mation of fibroblasts into iPSCs when combined with
OCT4 and SOX2 (Yamanaka and Takahashi, 2006). In
our case, we speculate that KLF4 and c-MYC activated
endogenous Sox9 and Runx2 gene expression during the re-
programming process to levels sufficient to give rise to os-
teo-chondrogenic lineages in vitro but not in vivo. They
could also gradually silence expression of the fibroblastic
marker Col1a1 from d1 to d6, which coincides with the
duration of transgene expression required for chondro-
genic induction, suggesting that complete silencing of
Col1a1 expression by the transgene is required for the for-
mation of osteo-chondroprogenitor-like cells. Addition of
SOX9 first directs and promotes the efficiency of cell re-
programming into osteo-chondrogenic-like cells, before
chondrogenic differentiation. This finding is consistent
with the role of SOX9 in specifying osteo-chondroprogeni-
tors and chondrogenic lineage by activating its down-
stream target genes (Col2a1, Sox5, and Sox6) during early
limb bud development (Akiyama et al., 2005; Bi et al.,
1999). In addition, the reprogrammed cells also expressed
high levels of CD9 and CD73 expression, which are low
in naive osteo-chondroprogenitors, and these surface
markers have been used to enrich an osteo-chondroproge-
nitor population with augmented bone-forming capacity
in vivo (Singh et al., 2015). Indeed, our transplantation
studies demonstrated the ability of reprogrammed cells to
differentiate into bone tissues subcutaneously and in the
fracture site. In contrast, these cells could undergo chon-
drogenic and osteogenic differentiation, but not adipocyte
differentiation, when cultured under differentiating condi-
tions, indicating that they possess osteo-chondrogenic po-
tential to a certain extent in vitro. However, we cannot rule
out the possibility that these reprogrammed osteo-chon-
drogenic cells have ‘‘endochondral-like’’ potential that
form bone via a cartilage intermediate in vivo. Collectively,
KMS-reprogrammed osteo-chondrogenic cells differ from
limb bud osteo-chondrogenitors, with unique cell surface
properties that confer their differentiation bias into osteo-
genic lineage.
In addition to reprogramming fibroblasts into chondro-
cytes, a recent study also demonstrated a direct conversion
of human placental cells to chondrocytes by a different set
of transcription factors (Ishii et al., 2012). Whether osteo-
chondrogenic cells could also be formed during this con-
version remains to be determined. Nevertheless, we report
here the use of defined factors to generate osteo-chondro-
genic cells with higher bone-forming potency from skin fi-
broblasts. This study has paved the way for the generation
of patient-specific osteo-chondrogenic cells as a possiblenew cell source for osteoblasts for the treatment of bone
defects.EXPERIMENTAL PROCEDURES
Mice and Cells
Mice were maintained in the Laboratory Animal Unit of the Uni-
versity of Hong Kong. All mouse studies were approved by the
Committee on the Use of Live Animals in Teaching and Research
and were carried out in accordance with institutional and interna-
tional standards and regulations. MDFs were isolated from dermis
of newborn Sox9-EGFP knockin (KI) mice. Skin tissues were manu-
ally dissociated and digested in 0.25% trypsin (Sigma) for 10–
15 min at 37C for 4 hr. After removing debris, cells were then
plated onto a 24-well plate and incubated in conventionalmedium
(DMEM [Gibco] plus 10% FBS [Biosera]).Viral Infection
Retroviral vectors (pMX) carrying mouse Klf4 (ID: 13370) and
c-Myc (ID: 13375) genes were purchased from Addgene deposited
by S. Yamanaka (Center for iPS Cell Research and Application
[CiRA], Kyoto University). pMX-Sox9was generated by subcloning
of mouse Sox9 full-length cDNA into a blunted pMX vector. Each
retroviral DNAwas transfected into Plat-E cells (a gift from A. Brad-
ley, Sanger Institute) at 8 3 106 cells per 10-cm dish by Lipofect-
amine 2000 (Invitrogen) and cultured with DMEM plus 10% FBS
in the absence of antibiotics overnight at 37C and 5% CO2. The
following day, cells were replaced with fresh medium and incu-
bated for another day. The virus-containing medium was then
collected and filtered through a 0.45-mmpore size cellulose acetate
filter before mixing with 4 mg/mL Polybrene (Sigma). The medium
in MDF culture dish was then replaced with 2 mL of Polybrene/vi-
rus-containing mixture in each well of a 24-well plate and incu-
bated overnight at 37C and 5% CO2. The following day, the
mixture was replaced with DMEM/10% FBS medium and moni-
tored daily for GFP expression for up to 2 weeks.
Doxycycline-inducible lentiviral constructs pLe6d-Ptight-hc-
MYC, pLe6d-Ptight-hF()SOX9, pLe6d-Ptight-hKLF4, and retro-
viral pMXs-gw/(rtTA2-M2) were gifts from N. Tsumaki (CiRA,
Kyoto University). Lentiviral vectors were transfected into 293T
cells at 6 3 10 6 cells per 10-cm dish by Lipofectamine 2000 re-
agent (Invitrogen) and ViraPowerPackaging Mix (Invitrogen) and
cultured in Opti-MEM Medium (Gibco) without serum in the
absence of antibiotics overnight at 37C and 5% CO2. The
following day, cells were replaced with fresh medium and incu-
bated for another day. Virus-containing supernatants were har-
vested 48–72 hr post transfection, concentrated by PEG-it (System
Bioscience), and stored at 80C. MDFs from Sox9-EGFP KI mice
were transduced with rtTA2-M2 retrovirus overnight prior to infec-
tion with inducible c-MYC, KLF4, and SOX9 lentiviruses for 48 hr
and replaced with fresh virus medium every 12 hr. Afterward,
MDFs were cultured with mTeSR in the absence or presence
of 1 mg/mL dox. Medium was replaced every other day. Dox was
withdrawn from the transduced MDFs every 2 days and cultured
until days 10–14 for immunofluorescence with GFP and Runx2
antibodies.Stem Cell Reports j Vol. 8 j 1587–1599 j June 6, 2017 1597
Flow Cytometry
Limb bud was dissected from both wild-type and Sox9-EGFP KI
mouse embryos at E10 and digested in 0.25% trypsin at 37C for
10min. Cells were then centrifuged at 1,000 rpm for 5min and re-
suspended in DMEM/10% FBS medium. Wild-type limb bud cells
were used for calibration in FACSAria I (Becton Dickinson) at the
Faculty Core Facility, Li Ka Shing Faculty of Medicine, the Univer-
sity of Hong Kong before proceeding to sort SOX9-EGFP+ cells. The
sorted GFP+ cells were collected in FBS and plated at 1 3 104 cells
per well in a 24-well plate in DMEM/10% FBS at 37C.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, and one table and can be found with
this article online at http://dx.doi.org/10.1016/j.stemcr.2017.
04.018.
AUTHOR CONTRIBUTIONS
Y.W., M.H.S., D.C., K.S.E.C., and M.C. planned the experiments;
Y.W., M.-H.W., and M.P.L.C. performed research and acquired
data; H.A. generated Sox9-EGFP knockin mice; M.H.S., D.C.,
K.S.E.C., and M.C. supervised the project; Y.W. and M.C. analyzed
data and wrote the manuscript.
ACKNOWLEDGMENTS
We thank Noriyuki Tsumaki for providing dox-inducible lentiviral
vectors, Allan Bradley for Plat-E cells, and Shinya Yamanaka for
pMX retroviral vectors. We also thank members of K.S.E.C. and
D.C. laboratories for their technical advice and assistance; tech-
nical staff in the Faculty Core Facility for assistance with cell sort-
ing; and J.A.I. Liu for assistance with figure preparation. This study
was supported by grants from the Research Grants Council
and University Grants Council of Hong Kong (AoE/M-04/04,
X_HKU708/14, GRF_17110715, and GRF_17123016 to Y.W. and
M.C., and AoE/M-04/04, T12-708/12-N to K.S.E.C.)
Received: January 19, 2015
Revised: April 14, 2017
Accepted: April 18, 2017
Published: May 18, 2017REFERENCES
Akiyama, H., Chaboissier, M.C., Martin, J.F., Schedl, A., and de
Crombrugghe, B. (2002). The transcription factor Sox9 has essen-
tial roles in successive steps of the chondrocyte differentiation
pathway and is required for expression of Sox5 and Sox6. Genes
Dev. 16, 2813–2828.
Akiyama, H., Kim, J.E., Nakashima, K., Balmes, G., Iwai, N., Deng,
J.M., Zhang, Z., Martin, J.F., Behringer, R.R., Nakamura, T., et al.
(2005). Osteo-chondroprogenitor cells are derived from Sox9 ex-
pressing precursors. Proc. Natl. Acad. Sci. USA 102, 14665–14670.
Amarilio, R., Viukov, S.V., Sharir, A., Eshkar-Oren, I., Johnson, R.S.,
and Zelzer, E. (2007). HIF1alpha regulation of Sox9 is necessary to
maintain differentiation of hypoxic prechondrogenic cells during
early skeletogenesis. Development 134, 3917–3928.1598 Stem Cell Reports j Vol. 8 j 1587–1599 j June 6, 2017Bell, D.M., Leung, K.K., Wheatley, S.C., Ng, L.J., Zhou, S., Ling,
K.W., Sham, M.H., Koopman, P., Tam, P.P., and Cheah, K.S.
(1997). SOX9 directly regulates the type-II collagen gene. Nat.
Genet. 16, 174–178.
Bi, W., Deng, J.M., Zhang, Z., Behringer, R.R., and de Crom-
brugghe, B. (1999). Sox9 is required for cartilage formation. Nat.
Genet. 22, 85–89.
Bridgewater, L.C., Lefebvre, V., and de Crombrugghe, B. (1998).
Chondrocyte-specific enhancer elements in the Col11a2 gene
resemble the Col2a1 tissue-specific enhancer. J. Biol. Chem. 273,
14998–15006.
Craft, A.M., Ahmed, N., Rockel, J.S., Baht, G.S., Alman, B.A., Kan-
del, R.A., Grigoriadis, A.E., and Keller, G.M. (2013). Specification
of chondrocytes and cartilage tissues from embryonic stem cells.
Development 140, 2597–2610.
Efe, J.A., Hilcove, S., Kim, J., Zhou,H., Ouyang, K.,Wang, G., Chen,
J., and Ding, S. (2011). Conversion of mouse fibroblasts into cardi-
omyocytes using a direct reprogramming strategy. Nat. Cell Biol.
13, 215–222.
Gaur, T., Lengner, C.J., Hovhannisyan, H., Bhat, R.A., Bodine, P.V.,
Komm, B.S., Javed, A., vanWijnen, A.J., Stein, J.L., Stein, G.S., et al.
(2005). Canonical WNT signaling promotes osteogenesis by
directly stimulating Runx2 gene expression. J. Biol. Chem. 280,
33132–33140.
Han, Y., and Lefebvre, V. (2008). L-Sox5 and Sox6 drive expression
of the aggrecan gene in cartilage by securing binding of Sox9 to a
far-upstream enhancer. Mol. Cell. Biol. 28, 4999–5013.
Handorf, A.M., and Li, W.J. (2011). Fibroblast growth factor-2
primes humanmesenchymal stem cells for enhanced chondrogen-
esis. PLoS One 6, e22887.
Hiramatsu, K., Sasagawa, S., Outani, H., Nakagawa, K., Yoshikawa,
H., and Tsumaki,N. (2011).Generation of hyaline cartilaginous tis-
sue from mouse adult dermal fibroblast culture by defined factors.
J. Clin. Invest. 121, 640–657.
Huang, P., He, Z., Ji, S., Sun, H., Xiang, D., Liu, C., Hu, Y., Wang, X.,
and Hui, L. (2011). Induction of functional hepatocyte-like cells
from mouse fibroblasts by defined factors. Nature 475, 386–389.
Hudson, J.E., Mills, R.J., Frith, J.E., Brooke, G., Jaramillo-Ferrada, P.,
Wolvetang, E.J., and Cooper-White, J.J. (2011). A defined medium
and substrate for expansion of human mesenchymal stromal cell
progenitors that enriches for osteo- and chondrogenic precursors.
Stem Cells Dev. 20, 77–87.
Hwang, Y.S., Polak, J.M., and Mantalaris, A. (2008). In vitro direct
chondrogenesis of murine embryonic stem cells by bypassing
embryoid body formation. Stem Cell Dev. 17, 971–978.
Ieda, M., Fu, J.D., Delgado-Olguin, P., Vedantham, V., Hayashi, Y.,
Bruneau, B.G., and Srivastava, D. (2010). Direct reprogramming of
fibroblasts into functional cardiomyocytes by defined factors. Cell
142, 375–386.
Ikeda, T., Kamekura, S., Mabuchi, A., Kou, I., Seki, S., Takato, T., Na-
kamura, K., Kawaguchi, H., Ikegawa, S., and Chung, U.I. (2004).
The combination of SOX5, SOX6, and SOX9 (the SOX trio) pro-
vides signals sufficient for induction of permanent cartilage.
Arthritis Rheum. 50, 3561–3573.
Ishii, R., Kami, D., Toyoda, M., Makino, H., Gojo, S., Ishii, T., and
Umezawa, A. (2012). Placenta to cartilage: direct conversion of hu-
man placenta to chondrocytes with transformation by defined fac-
tors. Mol. Biol. Cell. 23, 3511–3521.
Komori, T., Yagi, H., Nomura, S., Yamaguchi, A., Sasaki, K., Degu-
chi, K., Shimizu, Y., Bronson, R.T., Gao, Y.H., Inada, M., et al.
(1997). Targeted disruption of Cbfa1 results in a complete lack of
bone formation owing to maturational arrest of osteoblasts. Cell
89, 755–764.
Lefebvre, V., Li, P., and de Crombrugghe, B. (1998). A new long
form of Sox5 (L-Sox5), Sox6 and Sox9 are coexpressed in chondro-
genesis and cooperatively activate the type II collagen gene. EMBO
J. 17, 5718–5733.
Liu, F., Kohlmeier, S., and Wang, C.Y. (2008). Wnt signaling and
skeletal development. Cell Signal. 20, 999–1009.
Lorda-Diez, C.I., Montero, J.A., Martinez-Cue, C., Garcia-Porrero,
J.A., and Hurle, J.M. (2009). Transforming growth factors beta co-
ordinate cartilage and tendon differentiation in the developing
limb mesenchyme. J. Biol. Chem. 284, 29988–29996.
Nagy, A., Kenesi, E., Rentsendorj, O., Molnar, A., Szenasi, T., Sinko,
I., Zvara, A., Oommen, S.T., Barta, E., Puskas, L.G., et al. (2011).
Evolutionarily conserved, growth plate zone-specific regulation
of the matrilin-1 promoter: L-Sox5/Sox6 and Nfi factors bound
near TATA finely tune activation by Sox9. Mol. Cell. Biol. 31,
686–699.
Otto, F., Thornell, A.P., Crompton, T., Denzel, A., Gilmour, K.C.,
Rosewell, I.R., Stamp, G.W., Beddington, R.S., Mundlos, S., Olsen,
B.R., et al. (1997). Cbfa1, a candidate gene for cleidocranial
dysplasia syndrome, is essential for osteoblast differentiation and
bone development. Cell 89, 765–771.
Outani, H., Okada,M., Hiramatsu, K., Yoshikawa, H., and Tsumaki,
N. (2011). Induction of chondrogenic cells from dermal fibroblast
culture by defined factors does not involve a pluripotent state. Bio-
chem. Biophys. Res. Commun. 411, 607–612.
Outani, H., Okada, M., Yamashita, A., Nakagawa, K., Yoshikawa,
H., and Tsumaki, N. (2013). Direct induction of chondrogenic cells
fromhumandermal fibroblast culture by defined factors. PLoSOne
8, e77365.
Pang, Z.P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D.R.,
Yang, T.Q., Citri, A., Sebastiano, V., Marro, S., Sudhof, T.C., et al.
(2011). Induction of human neuronal cells by defined transcrip-
tion factors. Nature 476, 220–223.
Patel,M., andYang, S. (2010). Advances in reprogramming somatic
cells to induced pluripotent stem cells. Stem Cell Rev. 6, 367–380.
Pelttari, K., Steck, E., and Richter, W. (2008). The use of mesen-
chymal stem cells for chondrogenesis. Injury 39 (Suppl 1), S58–S65.
Qi, H., Jin, M., Duan, Y., Du, X., Zhang, Y., Ren, F., Wang, Y., Tian,
Q., Wang, X., Wang, Q., et al. (2014). FGFR3 induces degradation
of BMP type I receptor to regulate skeletal development. Biochim.
Biophys. Acta 1843, 1237–1247.
Qian, L., Huang, Y., Spencer, C.I., Foley, A., Vedantham, V., Liu, L.,
Conway, S.J., Fu, J.D., and Srivastava, D. (2012). In vivo reprogram-ming of murine cardiac fibroblasts into induced cardiomyocytes.
Nature 485, 593–598.
Singh, A., Lester, C., Drapp, R., Hu, D.Z., Glimcher, L.H., and Jones,
D. (2015). Tetraspanin CD9 and ectonucleotidase CD73 identify
an osteochondroprogenitor population with elevated osteogenic
properties. Development 142, 438–443.
Smits, P., Li, P.,Mandel, J., Zhang, Z., Deng, J.M., Behringer, R.R., de
Crombrugghe, B., and Lefebvre, V. (2001). The transcription fac-
tors L-Sox5 and Sox6 are essential for cartilage formation. Dev.
Cell 1, 277–290.
Song, B., Estrada, K.D., and Lyons, K.M. (2009). Smad signaling in
skeletal development and regeneration. Cytokine Growth Factor
Rev. 20, 379–388.
Sudo, K., Kanno, M., Miharada, K., Ogawa, S., Hiroyama, T., Saijo,
K., and Nakamura, Y. (2007). Mesenchymal progenitors able to
differentiate into osteogenic, chondrogenic, and/or adipogenic
cells in vitro are present in most primary fibroblast-like cell popu-
lations. Stem Cells 25, 1610–1617.
Szabo, E., Rampalli, S., Risueno, R.M., Schnerch, A., Mitchell, R.,
Fiebig-Comyn, A., Levadoux-Martin, M., and Bhatia, M. (2010).
Direct conversion of human fibroblasts to multilineage blood pro-
genitors. Nature 468, 521–526.
Thier, M.,Worsdorfer, P., Lakes, Y.B., Gorris, R., Herms, S., Opitz, T.,
Seiferling, D., Quandel, T., Hoffmann, P., Nothen, M.M., et al.
(2012). Direct conversion of fibroblasts into stably expandable
neural stem cells. Cell Stem Cell 10, 473–479.
Umeda, K., Oda, H., Yan, Q., Matthias, N., Zhao, J., Davis, B.R., and
Nakayama, N. (2015). Long-term expandable SOX9+ chondro-
genic ectomesenchymal cells from human pluripotent stem cells.
Stem Cell Rep. 4, 712–726.
Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., Sudhof, T.C.,
and Wernig, M. (2010). Direct conversion of fibroblasts to func-
tional neurons by defined factors. Nature 463, 1035–1041.
Wang, Y.H., Keenan, S.R., Lynn, J., McEwan, J.C., and Beck, C.W.
(2015). Gremlin1 induces anterior-posterior limb bifurcations in
developing Xenopus limbs but does not enhance limb regenera-
tion. Mech. Dev. 138 (Pt 3), 256–267.
Wu, L., Bluguermann, C., Kyupelyan, L., Latour, B., Gonzalez, S.,
Shah, S., Galic, Z., Ge, S., Zhu, Y., Petrigliano, F.A., et al. (2013).
Human developmental chondrogenesis as a basis for engineer-
ing chondrocytes from pluripotent stem cells. Stem Cell Rep. 1,
575–589.
Yamanaka, S., and Takahashi, K. (2006). Induction of pluripotent
stem cells from mouse fibroblast cultures. Tanpakushitsu Kakusan
Koso 51, 2346–2351.
Yamashita, A., Morioka, M., Yahara, Y., Okada, M., Kobayashi, T.,
Kuriyama, S., Matsuda, S., and Tsumaki, N. (2015). Generation of
scaffoldless hyaline cartilaginous tissue from human iPSCs. Stem
Cell Rep. 4, 404–418.
Yu, B., He, Z.Y., You, P., Han, Q.W., Xiang, D., Chen, F., Wang, M.J.,
Liu, C.C., Lin, X.W., Borjigin, U., et al. (2013). Reprogramming fi-
broblasts into bipotential hepatic stem cells by defined factors. Cell
Stem Cell 13, 328–340.Stem Cell Reports j Vol. 8 j 1587–1599 j June 6, 2017 1599
